News
DSRLF
80.95
NaN%
--
DiaSorin price target lowered to EUR 58 from EUR 68 at JPMorgan
TipRanks · 12/08 17:15
Invesco International Small-Mid Company Fund Q3 2025 Portfolio Positioning
Seeking Alpha · 11/05 08:56
Weekly Report: what happened at DSRLF last week (0908-0912)?
Weekly Report · 09/15 11:13
Weekly Report: what happened at DSRLF last week (0901-0905)?
Weekly Report · 09/08 11:16
Weekly Report: what happened at DSRLF last week (0825-0829)?
Weekly Report · 09/01 11:10
Weekly Report: what happened at DSRLF last week (0818-0822)?
Weekly Report · 08/25 11:21
Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis
Seeking Alpha · 08/21 13:52
Weekly Report: what happened at DSRLF last week (0811-0815)?
Weekly Report · 08/18 11:13
Bruker: Former Academia Customer Strength, Now Incredible Weakness
Seeking Alpha · 08/15 07:31
Weekly Report: what happened at DSRLF last week (0804-0808)?
Weekly Report · 08/11 11:20
Weekly Report: what happened at DSRLF last week (0728-0801)?
Weekly Report · 08/04 11:23
Weekly Report: what happened at DSRLF last week (0721-0725)?
Weekly Report · 07/28 11:24
Weekly Report: what happened at DSRLF last week (0714-0718)?
Weekly Report · 07/21 11:14
Weekly Report: what happened at DSRLF last week (0707-0711)?
Weekly Report · 07/14 11:23
Weekly Report: what happened at DSRLF last week (0630-0704)?
Weekly Report · 07/07 11:14
Weekly Report: what happened at DSRLF last week (0623-0627)?
Weekly Report · 06/30 11:21
Weekly Report: what happened at DSRLF last week (0616-0620)?
Weekly Report · 06/23 11:13
Weekly Report: what happened at DSRLF last week (0609-0613)?
Weekly Report · 06/16 11:20
Weekly Report: what happened at DSRLF last week (0602-0606)?
Weekly Report · 06/09 11:22
Weekly Report: what happened at DSRLF last week (0526-0530)?
Weekly Report · 06/02 11:31
More
Webull provides a variety of real-time DSRLF stock news. You can receive the latest news about Diasorin through multiple platforms. This information may help you make smarter investment decisions.
About DSRLF
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.